Equillium Inc (EQ) Stock Price, Quote & News

Company Profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 240 1200

Website: www.equilliumbio.com

Address:

2223 Avenida De La Playa, Suite 105, La Jolla, United States

bowlerhatsftw Nov. 14 at 7:51 PM

$EQ look at how clean this trigger is? Freaking alerr been going off all day. This is historical equilibrium

1 · Reply

SPYmyQQQ Nov. 14 at 6:50 PM

🎯 Target Hit 🏁 📨 From Nov 13, 2025 💊 $EQ 💵 Entry: $0.8900 ✅ Ext: $1.0465 💰 P/L: +17.58% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

bowlerhatsftw Nov. 14 at 4:01 PM

$EQ pricd alert triggered

0 · Reply

SPYmyQQQ Nov. 13 at 12:03 PM

🚀 New Signal ✅ 💊 $EQ 🗓️ Nov 13, 2025 💵 Entry: $0.8900 🎯 Target (Opt.): $1.05 (+17.58%) 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

BanditQ Nov. 12 at 7:20 PM

$EQ

1 · Reply

BanditQ Nov. 11 at 12:59 PM

$XBI $EQ very cheap. 90% we see positive results for ph1. Q1 2027. I got in early pt: $6-$7

0 · Reply

ENHSJH Nov. 10 at 6:15 PM

$EQ what the heck is going on here!! Down 55+ points in 5 days????

0 · Reply

BanditQ Nov. 5 at 8:02 PM

$PALI TRASHH, BUY $EQ INSTEAD!!!

1 · Reply

BanditQ Nov. 4 at 11:18 PM

$SRPT $EQ $12.

0 · Reply

BanditQ Nov. 4 at 5:48 AM

$SRPT buy $EQ phase 1 in Q1 2027. Pt: $12

0 · Reply

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 5, 2025, 6:21 PM EST - 9 days ago

Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript

Nov 4, 2025, 8:30 AM EST - 10 days ago

Equillium to Participate in Upcoming Investor Conferences

Nov 3, 2025, 4:05 PM EST - 11 days ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 22, 2025, 8:00 AM EDT - 23 days ago

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Oct 6, 2025, 4:02 PM EDT - 5 weeks ago

Equillium Announces Leadership and Corporate Updates

Sep 23, 2025, 5:30 AM EDT - 7 weeks ago

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Aug 29, 2025, 4:03 PM EDT - 2 months ago

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Aug 28, 2025, 5:35 PM EDT - 2 months ago

Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC

Aug 11, 2025, 8:30 AM EDT - 3 months ago

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Aug 4, 2025, 8:30 AM EDT - 3 months ago

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

May 6, 2025, 8:00 AM EDT - 6 months ago

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 1, 2025, 8:00 AM EDT - 7 months ago

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Apr 24, 2025, 9:00 AM EDT - 7 months ago

Equillium Announces Feedback from the U.S. Food and Drug Administration

Mar 27, 2025, 11:16 AM EDT - 8 months ago

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Mar 27, 2025, 7:00 AM EDT - 8 months ago

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Mar 27, 2025, 7:00 AM EDT - 8 months ago

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Feb 6, 2025, 8:00 AM EST - 10 months ago

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Nov 13, 2024, 4:01 PM EST - 1 year ago

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Nov 13, 2024, 8:00 AM EST - 1 year ago

Equillium to Present at the Stifel Healthcare Conference

Nov 12, 2024, 8:00 AM EST - 1 year ago

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Jul 18, 2024, 1:57 PM EDT - 1 year ago

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Equillium to be included in the Russell Microcap® Index

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

May 29, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Jefferies Global Healthcare Conference

May 14, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 9, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Dec 21, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Nov 13, 2023, 9:00 AM EST - 2 years ago

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Nov 8, 2023, 4:01 PM EST - 2 years ago

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 6, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Equillium to Host Analyst & Investor Day

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Sep 20, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Aug 9, 2023, 4:01 PM EDT - 2 years ago

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Equillium Announces $7.5 Million Share Repurchase Program

bowlerhatsftw Nov. 14 at 7:51 PM

$EQ look at how clean this trigger is? Freaking alerr been going off all day. This is historical equilibrium

1 · Reply

SPYmyQQQ Nov. 14 at 6:50 PM

🎯 Target Hit 🏁 📨 From Nov 13, 2025 💊 $EQ 💵 Entry: $0.8900 ✅ Ext: $1.0465 💰 P/L: +17.58% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

bowlerhatsftw Nov. 14 at 4:01 PM

$EQ pricd alert triggered

0 · Reply

SPYmyQQQ Nov. 13 at 12:03 PM

🚀 New Signal ✅ 💊 $EQ 🗓️ Nov 13, 2025 💵 Entry: $0.8900 🎯 Target (Opt.): $1.05 (+17.58%) 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

BanditQ Nov. 12 at 7:20 PM

$EQ

1 · Reply

BanditQ Nov. 11 at 12:59 PM

$XBI $EQ very cheap. 90% we see positive results for ph1. Q1 2027. I got in early pt: $6-$7

0 · Reply

ENHSJH Nov. 10 at 6:15 PM

$EQ what the heck is going on here!! Down 55+ points in 5 days????

0 · Reply

BanditQ Nov. 5 at 8:02 PM

$PALI TRASHH, BUY $EQ INSTEAD!!!

1 · Reply

BanditQ Nov. 4 at 11:18 PM

$SRPT $EQ $12.

0 · Reply

BanditQ Nov. 4 at 5:48 AM

$SRPT buy $EQ phase 1 in Q1 2027. Pt: $12

0 · Reply

BanditQ Nov. 3 at 10:28 PM

$SRPT should've bought $EQ, phase 1 results Q1 2027, get in early. Pt: $12

0 · Reply

BanditQ Nov. 3 at 10:27 PM

$SRPT you should all have bought $EQ , there is still time to get in, phase 1 results Q1 2027, get in early

0 · Reply

lifeonedge77 Oct. 31 at 1:14 PM

$CAN will outperform all of these companies $BITF $TLRY $STRO $EQ

0 · Reply

AceofDiamonds Oct. 29 at 11:24 PM

$EQ EQ504 for Ulcerative Colitis will sell during Phase 2 or sooner. Morphic sold to Lilly for 3.2 Billion Phase 2A, Prometheus to Merck for 10.2 Billion Phase 2A, and Protaganost to J & J for 900 million preclinical. It’s clear why ADAR1 and Janus gave 50 million plus to Equilium. Patience here is going to pay a HUGE payday in 2026.

1 · Reply

BanditQ Oct. 29 at 4:50 PM

$EQ

0 · Reply

lifeonedge77 Oct. 28 at 1:37 PM

One of these headed to $5 $GPUS $TLRY $EQ $CGC $STRO 🤔🤔💨💨💣🧨

1 · Reply